Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии, наркологии, психотерапии и клинической психологии ГБОУ ВПО Самарский государственный медицинский университет Минздрава России
Список исп. литературыСкрыть список 1. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. М.: Новый цвет, 2001. 2. Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. Schizophr Bull 1991; 17 (1): 113–32. 3. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784–8. 4. Andreasen NC, Nopoulos P, O’Leary DS et al. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry 1999; 46 (7): 908–20. 5. Baaré WF, Hulshoff Pol HE, Hijman R et al. Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol Psychiatry 1999; 45 (12): 1597–605. 6. Bleuler E. Dementia Praecox Or The Group Of Schizophrenias. New York, NY: International Universities Press, 1950. (Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Deutike, Leipzig, 1911.) 7. Bobes J, Arango C, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010; 71 (3): 280–6. 8. Bouricius JK. Negative symptoms and emotions in schizophrenia. Schizophr Bull 1989; 15 (2): 201–8. 9. Brekke JS, Levin S, Wolkon GH et al. Psychosocial functioning and subjective experience in schizophrenia. Schizophr Bull 1993; 19 (3): 599–608. 10. Choi J, Mogami T, Medalia A. Intrinsic motivation inventory: an adapted measure for schizophrenia research. Schizophr Bull 2010; 36 (5): 966–76. 11. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mo lNeurobiol 2006; 26 (4–6): 365–84. 12. Crow TJ. Brain changes and negative symptoms in schizophrenia. Psychopathology 1995; 28 (1): 18–21. 13. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980; 137: 383–6. 14. Darbà J, Minoves A, Rojo E et al. Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials. Rev Psiquiatr Salud Ment 2011; 4 (3): 126–43. 15. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization.Am J Psychiatry 1991; 148 (11): 1474–86. 16. de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70 (10): 1416–23. 17. Donohoe G, Morris DW, De Sanctis P et al. Early visual processing deficits in dysbindin-associated schizophrenia. Biol Psychiatry 2008; 63 (5): 484–9. 18. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5TM). American Psychiatric Association, 2013. 19. Eack SM, Mesholam-Gately RI, Greenwald DP et al. Negative symptom improvement during cognitive rehabilitation: results from 2-year trial of Cognitive Enhancement Therapy. Psychiatry Res 2013; 209 (1): 21–6. 20. Fervaha G, Agid O, Takeuchi H et al. Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. Schizophr Res 2013. Pii: S0920-9964(13)00568-9. doi: 10.1016/j.schres.2013.10.021. [Epub ahead of print] 21. Fervaha G, Graff-Guerrero A, Zakzanis KK et al. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. J Psychiatr Res 2013; 47 (11): 1590–6. 22. Fervaha G, Foussias G, Agid O, Remington G. A motivation and functional outcomes in early schizophrenia. Psychiatry Res 2013; 210 (2): 665–8. 23. Foussias G, Mann S, Zakzanis KK et al. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res 2011; 132 (1): 24–7. 24. Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship? Schizophr Bull 2006. 25. Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res 2012; 134 (2–3): 202–6. 26. Iizuka Y, Sei Y, Weinberger DR, Straub RE. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2-receptor internalization and signaling but not D1 internalization. J Neurosci 2007; 27 (45): 12390–5. 27. Janzarik W. Basic dynamic states in endogenous psychoses, with special reference to the pharmacotherapy of depressive states. Can Psychiatr Assoc J 1959; 4 (Suppl.): 195–7. 28. Karow A, Moritz S, Lambert M et al.; EGOFORS Initiative. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry 2012; 27 (6): 401–5. 29. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76. 30. Keefe RS, Harvey PD, Lenzenweger MF et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetaipaine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68. 31. Khodaie-Ardakani MR, Seddighi S, Modabbernia A et al. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res 2013; 47 (4): 472–8. 32. Kim DW, Shim M, Kim JI et al. Source Activation of P300 Correlates with Negative Symptom Severity in Patients with Schizophrenia. Brain Topogr 2013. [Epub ahead of print] 33. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32 (2): 214–9. 34. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, UK: E. & S. Livingston, 1919. 35. Kvajo M, McKellar H, Arguello PA et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA 2008; 105 (19): 7076–81. 36. Levkovitz Y, Mendlovich S, Riwkes S et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71 (2): 138–49. 37. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15 (12): 1995–2002. 38. Llorca PM, Blanc O, Samalin L et al.; EGOFORS Initiative. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiatry 2012; 27 (6): 396–400. 39. Lutgens D, Lepage M, Manchanda R, Malla A. Persistent negative symptoms in schizophrenia: survey of Canadian psychiatrists. Int Psychiatry 2013; 10 (3): 69–72. 40. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162 (3): 495–506. 41. Mueser KT, Douglas MS, Bellack AS, Morrison RL. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr Bull 1991; 17 (4): 565–82. 42. Mwansisya TE, Wang Z, Tao H et al. The diminished interhemispheric connectivity correlates with negative symptoms and cognitive impairment in first-episode schizophrenia. Schizophr Res 2013; 150 (1): 144–50. 43. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52 (12): 998–1007. 44. Potkin SG, Alva G, Fleming K et al. A PET study of the pathophysiology of negative symptoms in schizophrenia.Positron emission tomography.